Wedbush Securities’s Benitec Biopharma BNTC Stock Holding History

Wedbush Securities’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-78	Closed	-$40K	–	903
2018 Q2	$40K	Buy	+78	New	+$52.7K	0.01%	846
2017 Q4	–	Sell	-71	Closed	-$39K	–	862
2017 Q3	$39K	Sell	71 -35	-33%	-$18.7K	0.01%	811
2017 Q2	$50K	Buy	+106	New	+$67K	0.01%	802

Other funds holding BNTC

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities's BNTC Position: Q3 2018 in Review

Wedbush Securities sold out of Benitec Biopharma (BNTC) in Q3 2018, closing a stake of 78 shares — an estimated $40K sold.

Wedbush Securities first reported a position in BNTC in Q2 2017 and held it in 3 quarters. The position peaked at $50K in Q2 2017. 7 funds tracked by Wall St. Rank hold BNTC as of Q3 2018.

Wedbush Securities reported no remaining Benitec Biopharma position as of Q3 2018 after selling out during the quarter.
Wedbush Securities sold 78 Benitec Biopharma shares in Q3 2018, an estimated $40K.
Wedbush Securities first reported a position in Benitec Biopharma in Q2 2017 and held it in 3 quarters.
Wedbush Securities's Benitec Biopharma position peaked at $50K in Q2 2017.
7 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2018.

Based on Wedbush Securities's 13F filing for Q3 2018, filed 13 Nov 2018.